BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36693379)

  • 1. Higher-order SPOP assembly reveals a basis for cancer mutant dysregulation.
    Cuneo MJ; O'Flynn BG; Lo YH; Sabri N; Mittag T
    Mol Cell; 2023 Mar; 83(5):731-745.e4. PubMed ID: 36693379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of oligomer size modulates the competition between cluster formation and phase separation of the tumor suppressor SPOP.
    Sabri N; Cuneo MJ; Marzahn MR; Lee J; Bouchard JJ; Güllülü Ö; Vaithiyalingam S; Borgia MB; Schmit J; Mittag T
    J Biol Chem; 2023 Dec; 299(12):105427. PubMed ID: 37926283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
    Janouskova H; El Tekle G; Bellini E; Udeshi ND; Rinaldi A; Ulbricht A; Bernasocchi T; Civenni G; Losa M; Svinkina T; Bielski CM; Kryukov GV; Cascione L; Napoli S; Enchev RI; Mutch DG; Carney ME; Berchuck A; Winterhoff BJN; Broaddus RR; Schraml P; Moch H; Bertoni F; Catapano CV; Peter M; Carr SA; Garraway LA; Wild PJ; Theurillat JP
    Nat Med; 2017 Sep; 23(9):1046-1054. PubMed ID: 28805821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants.
    Zhang P; Gao K; Tang Y; Jin X; An J; Yu H; Wang H; Zhang Y; Wang D; Huang H; Yu L; Wang C
    Hum Mutat; 2014 Sep; 35(9):1142-51. PubMed ID: 24990631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ubiquitin ligase adaptor SPOP in cancer.
    Cuneo MJ; Mittag T
    FEBS J; 2019 Oct; 286(20):3946-3958. PubMed ID: 31495053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opposing Roles of
    Cavalcante L; Deshmukh SK; Ribeiro JR; Carneiro BA; Dizon DS; Angara K; Mattox T; Wu S; Xiu J; Walker P; Oberley M; Nabhan C; Huang H; Antonarakis ES
    JCO Precis Oncol; 2023 Sep; 7():e2300088. PubMed ID: 37677121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of speckle-type POZ protein (SPOP) in cancer development.
    Mani RS
    Drug Discov Today; 2014 Sep; 19(9):1498-502. PubMed ID: 25058385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Mutations of the Tumor Suppressor SPOP Disrupt the Formation of Active, Phase-Separated Compartments.
    Bouchard JJ; Otero JH; Scott DC; Szulc E; Martin EW; Sabri N; Granata D; Marzahn MR; Lindorff-Larsen K; Salvatella X; Schulman BA; Mittag T
    Mol Cell; 2018 Oct; 72(1):19-36.e8. PubMed ID: 30244836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
    Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C
    PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
    Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N
    Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
    Shi Q; Zhu Y; Ma J; Chang K; Ding D; Bai Y; Gao K; Zhang P; Mo R; Feng K; Zhao X; Zhang L; Sun H; Jiao D; Chen Y; Sun Y; Zhao SM; Huang H; Li Y; Ren S; Wang C
    Mol Cancer; 2019 Nov; 18(1):170. PubMed ID: 31771591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of oligomer size modulates the competition between cluster formation and phase separation of the tumor suppressor SPOP.
    Sabri N; Cuneo MJ; Marzahn MR; Lee J; Bouchard JJ; Vaithiyalingam S; Borgia MB; Schmit J; Mittag T
    bioRxiv; 2023 Mar; ():. PubMed ID: 36993550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Insights into BET Client Recognition of Endometrial and Prostate Cancer-Associated SPOP Mutants.
    Ostertag MS; Hutwelker W; Plettenburg O; Sattler M; Popowicz GM
    J Mol Biol; 2019 May; 431(11):2213-2221. PubMed ID: 31026449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deregulation of SPOP in Cancer.
    Zhang H; Jin X; Huang H
    Cancer Res; 2023 Feb; 83(4):489-499. PubMed ID: 36512624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover.
    Zhang P; Gao K; Jin X; Ma J; Peng J; Wumaier R; Tang Y; Zhang Y; An J; Yan Q; Dong Y; Huang H; Yu L; Wang C
    Cell Death Dis; 2015 Mar; 6(3):e1687. PubMed ID: 25766326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
    Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
    Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Roles of SPOP in DNA Damage Response and DNA Replication.
    Maekawa M; Higashiyama S
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher-order oligomerization promotes localization of SPOP to liquid nuclear speckles.
    Marzahn MR; Marada S; Lee J; Nourse A; Kenrick S; Zhao H; Ben-Nissan G; Kolaitis RM; Peters JL; Pounds S; Errington WJ; Privé GG; Taylor JP; Sharon M; Schuck P; Ogden SK; Mittag T
    EMBO J; 2016 Jun; 35(12):1254-75. PubMed ID: 27220849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.
    Ma J; Chang K; Peng J; Shi Q; Gan H; Gao K; Feng K; Xu F; Zhang H; Dai B; Zhu Y; Shi G; Shen Y; Zhu Y; Qin X; Li Y; Zhang P; Ye D; Wang C
    J Exp Clin Cancer Res; 2018 Jul; 37(1):145. PubMed ID: 29996942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
    Wang H; Barbieri CE; He J; Gao Y; Shi T; Wu C; Schepmoes AA; Fillmore TL; Chae SS; Huang D; Mosquera JM; Qian WJ; Smith RD; Srivastava S; Kagan J; Camp DG; Rodland KD; Rubin MA; Liu T
    J Transl Med; 2017 Aug; 15(1):175. PubMed ID: 28810879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.